NSRX
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Graham Number and Intrinsic Value are unavailable due to lack of earnings/EPS.
- P/B of 8.79 is excessive for a non-earning entity
- No P/E or PEG available due to lack of earnings
Future value is entirely dependent on clinical/regulatory catalysts rather than financial growth.
- Aggressive analyst price targets
- No reported revenue growth
- No earnings growth
Historical performance shows a sustained loss of investor confidence.
- Consistent decline across 1Y, 3Y, and 5Y timeframes (-67.3%)
Strong balance sheet liquidity is offset by poor operational efficiency and negative returns.
- Low leverage (Debt/Equity 0.04)
- Strong current ratio
- Piotroski F-Score of 3/9 is in the 'Weak' category
Company is in a growth/survival phase; no capital returned to shareholders.
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for NSRX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
NSRX
Nasus Pharma Ltd.
Primary
|
-67.3% | -67.3% | -67.3% | -65.3% | +21.6% | -20.6% |
|
IGC
IGC Pharma, Inc.
Peer
|
-80.2% | -8.6% | +6.7% | -23.8% | +23.1% | 0.0% |
|
EKSO
Ekso Bionics Holdings, Inc.
Peer
|
-91.1% | -64.0% | +54.0% | +66.6% | -27.2% | -18.0% |
|
NEPH
Nephros, Inc.
Peer
|
-63.0% | +102.8% | +42.6% | -46.5% | -1.4% | +3.6% |
|
MYO
Myomo, Inc.
Peer
|
-91.9% | +46.4% | -82.9% | -17.9% | +23.8% | -3.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
NSRX
Nasus Pharma Ltd.
|
BEARISH | $31.62M | - | -% | -% | $2.7 | |
|
IGC
IGC Pharma, Inc.
|
BEARISH | $31.63M | - | -83.3% | -% | $0.32 | Compare |
|
EKSO
Ekso Bionics Holdings, Inc.
|
BEARISH | $31.11M | - | -107.6% | -91.4% | $8.73 | Compare |
|
NEPH
Nephros, Inc.
|
BEARISH | $30.66M | 26.18 | 12.7% | 6.4% | $2.88 | Compare |
|
MYO
Myomo, Inc.
|
BEARISH | $30.5M | - | -86.2% | -38.1% | $0.79 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-22 | TELEMAN DAN BENJAMIN | Chief Executive Officer | Purchase | 2,900 | $10,904 |
| 2026-03-31 | TELEMAN DAN BENJAMIN | Chief Executive Officer | Purchase | 15,000 | $30,600 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
NSRX submitted its 20-F annual report on March 25, 2026, providing the required comprehensive disclosure of its financial position and operational results. The filing serves as the primary source for the company's annual financial highlights and associated risk factors for the reporting period.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning NSRX from our newsroom.